LONDON (Reuters), -The European Union Drug Regulator expects to publish the results of its investigation of Moderna (NASDAQ)’s COVID-19 booster vaccination and begin a rolling review next week of Merck’s antiviral medication molnupiravir. A senior official announced this on Thursday.
Marco Cavaleri is the head of bio-health threats and vaccines strategy of the European Medicines Agency (EMA). He stated that results from the Moderna boost shot will be released on October 25, in a briefing.
It was unclear if Russia would apply for the COVID one-dose vaccine, Sputnik Light, as well as for the two-dose Sputnik V shot.
Watchdog Pfizer BioNTech boosters were approved by the FDA on October 4. The agency recommended that anyone with weaker immune systems receive Moderna or a third Pfizer BioNTech shot.
The member states were free to determine if the booster should be given to the larger population.
Interim data from Merck showed that Merck’s antiviral experimental pill may reduce the chance of death or hospitalisation for patients most susceptible to severe COVID-19.
Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.